

Oncology Clinical Pathways

Mesothelioma

March 2024 – V1.2024



Choose **VA**



SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Table of Contents

[Presumptive Conditions](#).....3

[Pleural Epithelioid](#).....4

[Sarcomatoid or Biphasic](#).....5




Mesothelioma – Presumptive Conditions

VA automatically presumes that certain disabilities were caused by military service. This is because of the unique circumstances of a specific Veteran's military service. If a presumed condition is diagnosed in a Veteran within a certain group, they can be awarded disability compensation.

Mesothelioma is not currently listed as a presumptive condition.

For more information, please visit [U.S. Department of Veterans Affairs - Presumptive Disability Benefits \(va.gov\)](https://www.va.gov/opa/whatsnew/presumptive-disability-benefits)

Mesothelioma – Pleural Epithelioid



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.


^a **Refer to Genetics for Counseling** comprehensive genomic profiling (CGP) and PD-L1 expression is not recommended in mesothelioma

^b **Candidate for Bevacizumab** received cisplatin plus pemetrexed in the first-line setting; ECOG PS 0-2; not amenable to curative surgery; due to anti-VEGF effects patients with the following should not receive bevacizumab: non-healing wound/fracture, major surgery in prior 4 weeks, bleeding disorder or coagulopathy, recent history of GI perforation, unstable cardiac condition [uncontrolled HTN, arterial thromboembolism, symptomatic CHF (NYHA II-IV), recent MI or CVA, uncontrolled angina or arrhythmia], use of antiplatelet therapy (aspirin ≥325 mg/day, dipyridol, ticlopidine, dipyridamole), anti-vitamin K drugs at curative dose, LMWH at curative dose, use of NSAIDs

^c **Pleurectomy** patient a candidate if NO disease, low burden pleural disease, limited chest wall involvement

^d **Progression** if patient is symptomatic, consider referral to Radiation Oncology for palliative therapy

Mesothelioma – Sarcomatoid or Biphasic



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

^a **Ipilimumab** dosing of 1mg/kg every 6 weeks
^b **Progression** if patient is symptomatic, consider referral to Radiation Oncology for palliative therapy